Current research on respiratory viral infections: Third International Symposium

Antiviral Research

Volumn 50, Issue 3, 2001, Pages 157-196

  Schmidt, Alexander C ^a   Couch, Robert B ^b   Galasso, George J ^c   Hayden, Frederick G ^d   Mills, John ^e   Murphy, Brian R ^a   Chanock, Robert M ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c The Macrae Group   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

^e Macfarlane Burnet Ctr for Med Res   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; CL 387626; DEXAMETHASONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; INDOMETACIN; INFLUENZA VACCINE; LIVE VACCINE; MEVINOLIN; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MYCOPHENOLIC ACID; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OSELTAMIVIR; PALIVIZUMAB; PERAMIVIR; PLECONARIL; PNEUMOCOCCUS VACCINE; R 170591; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS VACCINE; RFI 461; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; RIBAVIRIN; RIMANTADINE; RUPINTRIVIR; SB 242235; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG; VIRULENCE FACTOR; VIRUS PROTEIN; ZANAMIVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CONFERENCE PAPER; DIAGNOSTIC VALUE; EPIDEMIC; HUMAN; HUMAN ADENOVIRUS 2; IMMUNE DEFICIENCY; IMMUNE RESPONSE; INFECTION RISK; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A; INFLUENZA VIRUS B; NONHUMAN; OTITIS MEDIA; PARAINFLUENZA VIRUS 2; PARAINFLUENZA VIRUS 3; PATHOGENESIS; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; RHINOVIRUS; SIDE EFFECT; VACCINE PRODUCTION; VIRUS DETECTION; VIRUS LOAD; VIRUS MORPHOLOGY; VIRUS VIRULENCE;

ADENOVIRIDAE; ANIMALS; ANTIVIRAL AGENTS; DISEASE OUTBREAKS; HUMANS; ORTHOMYXOVIRIDAE; RESPIRATORY SYNCYTIAL VIRUSES; RESPIRATORY TRACT INFECTIONS; RHINOVIRUS; RISK FACTORS; VACCINES;

ADENOVIRIDAE; BACTERIA (MICROORGANISMS); HUMAN ADENOVIRUS; HUMAN ADENOVIRUS TYPE 2; HUMAN PARAINFLUENZA VIRUS 2; HUMAN PARAINFLUENZA VIRUS 3; INFLUENZA A VIRUS; INFLUENZA VIRUS; INFLUENZAVIRUS B; PARAMYXOVIRIDAE; PNEUMOCOCCUS; RESPIRATORY SYNCYTIAL VIRUS; RHINOVIRUS; RICE STRIPE VIRUS; SYNCYTIAL VIRUS;

EID: 0035009660     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(01)00136-X     Document Type: Conference Paper

References (156)

1. Adenovirus type 37 uses sialic acid as a cellular receptor
2. Variable morbidity of respiratory syncytial virus infection in patients with underlying lung disease: A review of the PICNIC RSV database. Pediatric Investigators Collaborative Network on Infections in Canada
3. Respiratory virus infection as a cause of prolonged symptoms in acute otitis media
4. Cold adaptation of parainfluenza virus type 3: Induction of three phenotypic markers
5. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children
6. Cutting edge: Adenovirus E19 has two mechanisms for affecting class I MHC expression
7. The M2-2 protein of human respiratory syncytial virus is a regulatory factor involved in the balance between RNA replication and transcription
8. Structural analysis of the mechanism of adenovirus binding to its human cellular receptor, CAR
9. The detection of viral genomes by polymerase chain reaction in the myocardium of pediatric patients with advanced HIV disease
10. Infections in 18 000 infants and children in a controlled study of respiratory tract disease. II. Variation in adenovirus infections by year and season
11. Chimeric bovine respiratory syncytial virus with glycoprotein gene substitutions from human respiratory syncytial virus (HRSV): Effects on host range and evaluation as a live-attenuated HRSV vaccine
12. Interferon gamma expressed by a recombinant respiratory syncytial virus attenuates virus replication in mice without compromising immunogenicity
13. Partial protection to respiratory syncytial virus (RSV) elicited in mice by intranasal immunization using live staphylococci with surface- displayed RSV-peptides
14. Isolation of subgenus B adenovirus during a fatal outbreak of enterovirus 71-associated hand, foot, and mouth disease in Sibu, Sarawak
15. Influenza A and meningococcal disease
16. The role of nasal secretion and serum antibody in the rhinovirus common cold
17. Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). I. Isolation, properties and characterization
18. Newly recognized myxoviruses from children with respiratory disease
19. Growth on artificial medium of an agent associated with atypical pneumonia and its identification as PPLO
20. Isolation and characterization of adenovirus 5 from the brain of an infant with fatal cerebral edema
21. Respiratory viruses interfere with bacteriologic response to antibiotic in children with acute otitis media
22. Parainfluenza Viruses
23. Rational design of live-attenuated recombinant vaccine virus for human respiratory syncytial virus by reverse genetics
24. Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5′ proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development
25. Recovery of viruses other than cytomegalovirus from bronchoalveolar lavage fluid
26. Immunity to influenza in man
27. Immunization of types four and seven adenoviruses by selective infection of the intestinal tract
28. Respiratory viral infections in immunocompetent and immunocompromised persons
29. Host responses to respiratory virus infection and immunization
30. Satisfactorily attenuated and protective mutants derived from a partially attenuated cold-passaged respiratory syncytial virus mutant by introduction of additional attenuating mutations during chemical mutagenesis
31. Recombinant human respiratory syncytial virus (RSV) monoclonal antibody Fab is effective therapeutically when introduced directly into the lungs of RSV-infected mice
32. The molecular basis of pneumococcal infection: A hypothesis
33. Rehospitalization for respiratory illness in infants of less than 32 weeks' gestation
34. Acute respiratory viral infections in ambulatory children of urban northeast Brazil
35. Heparan sulfate glycosaminoglycans are involved in adenovirus type 5 and 2-host cell interactions
36. Comparison of rapid diagnostic techniques for respiratory syncytial and influenza A virus respiratory infections in young children
37. Human parainfluenza virus type 3 (PIV3) expressing the hemagglutinin protein of measles virus provides a potential method for immunization against measles virus and PIV3 in early infancy
38. Prolonged survival of pancreatic islet allografts mediated by adenovirus immunoregulatory transgenes
39. Rapid diagnosis of respiratory syncytial virus infections in immunocompromised adults
40. Mechanism of protective immunity against influenza virus infection in mice without antibodies
41. Efficacy of a Pneumococcal Conjugate Vaccine against Acute Otitis Media
42. Huntingtin interacts with a family of WW domain proteins
43. Rapid simultaneous diagnosis of infections with respiratory syncytial viruses A and B, influenza viruses A and B, and human parainfluenza virus types 1, 2, and 3 by multiplex quantitative reverse transcription- polymerase chain reaction-enzyme hybridization assay (Hexaplex)
44. Detection of viral, Chlamydia pneumoniae and Mycoplasma pneumoniae infections in exacerbations of asthma in children
45. Low-temperature-grown RS virus in adult volunteers
46. Cytoplasmic inclusions of respiratory syncytial virus-infected cells: Formation of inclusion bodies in transfected cells that coexpress the nucleoprotein, the phosphoprotein, and the 22K protein
47. Surfactant protein A binds to the fusion glycoprotein of respiratory syncytial virus and neutralizes virion infectivity
48. Experimental otitis media after nasal inoculation of Streptococcus pneumoniae and influenza A virus in chinchillas
49. Role of early region 3 (E3) in pathogenesis of adenovirus disease
50. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level
51. Risk of primary infection and reinfection with respiratory syncytial virus
52. Safety and immunogenicity of intranasally administered inactivated trivalent virosome-formulated influenza vaccine containing Escherichia coli heat-labile toxin as a mucosal adjuvant
53. Evaluation of the live attenuated cpts 248/404 RSV vaccine in combination with a subunit RSV vaccine (PFP-2) in healthy young and older adults
54. Adult adenovirus infections: Loss of orphaned vaccines precipitates military respiratory disease epidemics
55. Respiratory syncytial virus infection in children with bronchopulmonary dysplasia
56. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group
57. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants
58. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group
59. Molecular characterization of H9N2 influenza viruses: Were they the donors of the 'internal' genes of H5N1 viruses in Hong Kong?
60. Respiratory syncytial viral infection in children with compromised immune function
61. Prevalence of various respiratory viruses in the middle ear during acute otitis media
62. A longitudinal study of respiratory viruses and bacteria in the etiology of acute otitis media with effusion
63. Recovery of a new agent from patients with acute respiratory disease
64. Characterization of the influenza A virus gene pool in avian species in southern China: Was H6N1 a derivative or a precursor of H5N1?
65. Adenovirus immunoregulatory genes and their cellular targets
66. Prevention of adenoviral acute respiratory disease in Army recruits: Cost-effectiveness of a military vaccination policy
67. Fimbria-mediated enhanced attachment of nontypeable Haemophilus influenzae to respiratory syncytial virus-infected respiratory epithelial cells
68. Respiratory syncytial virus that lacks open reading frame 2 of the M2 gene (M2-2) has altered growth characteristics and is attenuated in rodents
69. Recombinant respiratory syncytial viruses with deletions in the NS1, NS2, SH, and M2-2 genes are attenuated in vitro and in vivo
70. Community study of role of viral infections in exacerbations of asthma in 9-11 year old children
71. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus
72. First International Symposium on Influenza and Other Respiratory Viruses: Summary and overview: Kapalua, Maui, Hawaii, 4-6 December 1998
73. Evaluation of a live attenuated bovine parainfluenza type 3 vaccine in two- to six-month-old infants
74. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in healthy infants and children
75. Severe respiratory syncytial virus disease in Alaska native children
76. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine
77. Clinical and immunological response of infants and children to administration of low-temperature adapted respiratory syncytial virus
78. Influenza A and B virus infection in infants and young children during the years 1957-1976
79. Negative-strand virus M and retrovirus MA proteins: All in a family?
80. Interaction of an adenovirus 14.7-kilodalton protein inhibitor of tumor necrosis factor alpha cytolysis with a new member of the GTPase superfamily of signal transducers
81. Interaction of an adenovirus E3 14.7-kilodalton protein with a novel tumor necrosis factor alpha-inducible cellular protein containing leucine zipper domains
82. Recombinant influenza A virus vaccines for the pathogenic human A/Hong Kong/97 (H5N1) viruses
83. Identification of a cell protein (FIP-3) as a modulator of NF-κB activity and as a target of an adenovirus inhibitor of tumor necrosis factor α-induced apoptosis
84. Do L3T4 + T cells act as effector cells in protection against influenza virus infection
85. Avian-to-human transmission of H9N2 subtype influenza A viruses: Relationship between H9N2 and H5N1 human isolates
86. An adenovirus inhibitor of tumor necrosis factor alpha-induced apoptosis complexes with dynein and a small GT-Pase
87. Biologic and immunologic characteristics of cold-adapted influenza virus
88. The development of live attenuated cold-adapted influenza virus vaccine for humans
89. Respiratory syncytial viral infection in infants with congenital heart disease
90. Increased burden of respiratory viral associated severe lower respiratory tract infections in children infected with human immunodeficiency virus type-1
91. Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein
92. Measuring the comparative efficacy of antibacterial agents for acute otitis media: The 'Pollyanna phenomenon'
93. Epidemiology of respiratory viral infection among paediatric inpatients over a 6 year period in north-east England
94. Acute myocarditis. Rapid diagnosis by PCR in children
95. Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes
96. Cytotoxic T-cell immunity to influenza
97. Does prematurity alter the course of respiratory syncytial virus infection?
98. The economic impact of pandemic influenza in the United States: Priorities for intervention
99. Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons
100. Current research on influenza and other respiratory viruses: II international symposium
101. Use of live attenuated cold-adapted influenza A reassortant virus vaccines in infants, children, young adults and elderly adults
102. Temperature-sensitive mutants of influenza A virus. Transfer of the two ts-1A2 ts lesions present in the Udorn/72-ts-1A2 donor virus to the influenza A/Alaska/6/77 (H3N2) wild type virus
103. Effect of age and preexisting antibody on serum antibody response of infants and children to the F and G glycoproteins during respiratory syncytial virus infection
104. Current approaches to the development of vaccines effective against parainfluenza and respiratory syncytial viruses
105. Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. Pediatric Investigators Collaborative Network on Infections in Canada
106. Effect of rapid diagnosis on management of influenza A infections
107. The p38 signal transduction pathway: Activation and function
108. Epidemiology of respiratory syncytial virus infection in Washington, DC II. Infection and disease with respect to age, immunologic status, race and sex
109. RhoA interacts with the fusion glycoprotein of respiratory syncytial virus and facilitates virus-induced syncytium formation
110. A RhoA-derived peptide inhibits syncytium formation induced by respiratory syncytial virus and parainfluenza virus type 3
111. Effect of respiratory syncytial virus on adherence, colonization and immunity of non-typable Haemophilus influenzae: Implications for otitis media
112. Detection of adenoviral genome in the myocardium of adult patients with idiopathic left ventricular dysfunction
113. Paramyxovirus M proteins: Pulling it all together and putting it on the road
114. Human infection with influenza H9N2
115. Unexplained deaths due to possibly infectious causes in the United States: Defining the problem and designing surveillance and laboratory approaches. The Unexplained Deaths Working Group
116. Adherence of type I Streptococcus pneumoniae to tracheal epithelium of mice infected with influenza A/PR8 virus
117. Immunoprophylaxis and immunotherapy of respiratory syncytial virus infection in the cotton rat
118. Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats
119. Rhinovirus and respiratory syncytial virus in wheezing children requiring emergency care. IgE and eosinophil analyses
120. Infection with respiratory syncytial virus enhances expression of native receptors for non-pilate Neisseria meningitidis on HEp-2 cells
121. Induction of protective immunity against influenza virus in a macaque model: Comparison of conventional and iscom vaccines
122. Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae
123. Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture
124. Human antibody responses to mature and immature forms of viral envelope in respiratory syncytial virus infection: Significance for subunit vaccines
125. Bovine respiratory syncytial virus nonstructural proteins NS1 and NS2 cooperatively antagonize α/β interferon-induced antiviral response
126. Bovine parainfluenza virus type 3 (BPIV3) fusion and hemagglutinin-neuraminidase glycoproteins make an important contribution to the restricted replication of BPIV3 in primates
127. Bacterial pneumonia during the Hong Kong influenza epidemic of 1968-1969
128. Molecular identification of viruses in sudden infant death associated with myocarditis and pericarditis
129. Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease
130. Respiratory syncytial virus infection in north-east England
131. Identification of mutations contributing to the temperature-sensitive, cold-adapted, and attenuation phenotypes of the live-attenuated cold-passage 45 (cp45) human parainfluenza virus 3 candidate vaccine
132. Effectiveness of Palivizumab: Evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season
133. The role of human adenovirus early region 3 proteins (gp19K, 10.4K, 14.5K, and 14.7K) in a murine pneumonia model
134. Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness
135. Non-typeable Haemophilus influenzae adhere to and invade human bronchial epithelial cells via an interaction of lipooligosaccharide with the PAF receptor
136. Avirulent Avian influenza virus as a vaccine strain against a potential human pandemic
137. Recombinant respiratory syncytial virus that does not express the NS1 or M2-2 protein is highly attenuated and immunogenic in chimpanzees
138. Prophylaxis against respiratory syncytial virus in premature infants
139. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: A randomized controlled trial
140. A triple beta-spiral in the adenovirus fibre shaft reveals a new structural motif for a fibrous protein
141. Therapy for respiratory tract infections caused by respiratory syncytial virus
142. Expression of adenoviral E3 transgenes in beta cells prevents autoimmune diabetes
143. Respiratory syncytial virus infection in tropical and developing countries
144. Community respiratory virus infections in immunocompromised patients with cancer
145. Recombinant respiratory syncytial virus (RSV) bearing a deletion of either the NS2 or SH gene is attenuated in chimpanzees
146. Replacement of the F and G proteins of respiratory syncytial virus (RSV) subgroup A with those of subgroup B generates chimeric live attenuated RSV subgroup B vaccine candidates
147. Immune responses to adenoviruses: Viral evasion mechanisms and their implications for the clinic
148. Evaluation of a Live, Cold-Passaged, Temperature-Sensitive, Respiratory Syncytial Virus Vaccine Candidate in Infancy
149. CL387626 exhibits marked and unusual antiviral activity against respiratory syncytial virus in tissue culture and in cotton rats
150. Genetic characterization of the pathogenic influenza A/Goose/Guangdong/1/96 (H5N1) virus: Similarity of its hemagglutinin gene to those of H5N1 viruses from the 1997 outbreaks in Hong Kong